93 related articles for article (PubMed ID: 14574438)
21. Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes.
O'Tuathaigh CM; Hryniewiecka M; Behan A; Tighe O; Coughlan C; Desbonnet L; Cannon M; Karayiorgou M; Gogos JA; Cotter DR; Waddington JL
Neuropsychopharmacology; 2010 Oct; 35(11):2262-73. PubMed ID: 20631688
[TBL] [Abstract][Full Text] [Related]
22. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia.
Karayiorgou M; Simon TJ; Gogos JA
Nat Rev Neurosci; 2010 Jun; 11(6):402-16. PubMed ID: 20485365
[TBL] [Abstract][Full Text] [Related]
23. Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice.
Käenmäki M; Tammimäki A; Garcia-Horsman JA; Myöhänen T; Schendzielorz N; Karayiorgou M; Gogos JA; Männistö PT
Br J Pharmacol; 2009 Dec; 158(8):1884-94. PubMed ID: 19930170
[TBL] [Abstract][Full Text] [Related]
24. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.
van den Buuse M
Schizophr Bull; 2010 Mar; 36(2):246-70. PubMed ID: 19900963
[TBL] [Abstract][Full Text] [Related]
25. COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo.
Hirvonen MM; Någren K; Rinne JO; Pesonen U; Vahlberg T; Hagelberg N; Hietala J
Mol Imaging Biol; 2010 Apr; 12(2):192-7. PubMed ID: 19795175
[TBL] [Abstract][Full Text] [Related]
26. Animal models of gene-environment interactions in schizophrenia.
Ayhan Y; Sawa A; Ross CA; Pletnikov MV
Behav Brain Res; 2009 Dec; 204(2):274-81. PubMed ID: 19379776
[TBL] [Abstract][Full Text] [Related]
27. Behavioral genetic contributions to the study of addiction-related amphetamine effects.
Phillips TJ; Kamens HM; Wheeler JM
Neurosci Biobehav Rev; 2008; 32(4):707-59. PubMed ID: 18207241
[TBL] [Abstract][Full Text] [Related]
28. The evolution of drug development in schizophrenia: past issues and future opportunities.
Carpenter WT; Koenig JI
Neuropsychopharmacology; 2008 Aug; 33(9):2061-79. PubMed ID: 18046305
[TBL] [Abstract][Full Text] [Related]
29. The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging.
Schott BH; Seidenbecher CI; Fenker DB; Lauer CJ; Bunzeck N; Bernstein HG; Tischmeyer W; Gundelfinger ED; Heinze HJ; Düzel E
J Neurosci; 2006 Feb; 26(5):1407-17. PubMed ID: 16452664
[TBL] [Abstract][Full Text] [Related]
30. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.
Seeman P; Weinshenker D; Quirion R; Srivastava LK; Bhardwaj SK; Grandy DK; Premont RT; Sotnikova TD; Boksa P; El-Ghundi M; O'dowd BF; George SR; Perreault ML; Männistö PT; Robinson S; Palmiter RD; Tallerico T
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3513-8. PubMed ID: 15716360
[TBL] [Abstract][Full Text] [Related]
31. Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.
Forsberg MM; Juvonen RO; Helisalmi P; Leppänen J; Gogos JA; Karayiorgou M; Männistö PT
Naunyn Schmiedebergs Arch Pharmacol; 2004 Oct; 370(4):279-89. PubMed ID: 15378229
[TBL] [Abstract][Full Text] [Related]
32. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
[TBL] [Abstract][Full Text] [Related]
33. The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review.
Dahoun T; Trossbach SV; Brandon NJ; Korth C; Howes OD
Transl Psychiatry; 2017 Jan; 7(1):e1015. PubMed ID: 28140405
[TBL] [Abstract][Full Text] [Related]
34. The role of catechol-O-methyltransferase in reward processing and addiction.
Tunbridge EM; Huber A; Farrell SM; Stumpenhorst K; Harrison PJ; Walton ME
CNS Neurol Disord Drug Targets; 2012 May; 11(3):306-23. PubMed ID: 22483300
[TBL] [Abstract][Full Text] [Related]
35. D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice.
Huotari M; García-Horsman JA; Karayiorgou M; Gogos JA; Männistö PT
Psychopharmacology (Berl); 2004 Feb; 172(1):1-10. PubMed ID: 14574438
[TBL] [Abstract][Full Text] [Related]
36. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice.
Huotari M; Santha M; Lucas LR; Karayiorgou M; Gogos JA; Männistö PT
J Pharmacol Exp Ther; 2002 Dec; 303(3):1309-16. PubMed ID: 12438556
[TBL] [Abstract][Full Text] [Related]
37. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.
Huotari M; Gogos JA; Karayiorgou M; Koponen O; Forsberg M; Raasmaja A; Hyttinen J; Männistö PT
Eur J Neurosci; 2002 Jan; 15(2):246-56. PubMed ID: 11849292
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
